Dendreon Corporation, developer of the first ever FDA-approved cellular immunotherapy, announced on 10 November that it had filed for protection from its creditors under Chapter 11 of the US Bankruptcy Code. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals